BiliAAP
BiliAAP is a medical tool designed to assist clinicians in managing newborn hyperbilirubinemia by applying American Academy of Pediatrics and NICE (2025) guidelines. The app provides clinical decision support through risk-stratified algorithms, automated calculations, and visual trend analysis for bilirubin levels.
Overview · Full Intel report in progress
The App DNA
What makes this app unique?
For Pediatricians and neonatal healthcare professionals.
What does it look like?
Key features
Provides algorithms for hyperbilirubinemia management based on AAP and NICE (2025) guidelines.
Allows users to plot up to two time points to assess bilirubin trends and calculate rates of increase.
Evaluates neurotoxicity risk factors and gestational age to determine appropriate risk curves.
Supports calculations in both mg/dl and µmol/L with extended graphs covering 0 to 336 hours.
How much does it cost?
Velocity
Steady developmentShow more...
5 versions in history. Development pace: steady.
Who built it?
Gerson Rodriguez
9 apps tracked · Medical
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for BiliAAP
How's the Medical market?
The rivals identified
By Jeffrey Fulton
Both apps target clinicians managing neonatal hyperbilirubinemia, competing directly on clinical decision support for bilirubin levels and guideline application.
- BiliAAP integrates 2025 NICE guidelines, while the rival relies on older 2004 and 2022 AAP standards.
- BiliAAP costs 3.99 dollars, significantly lower than the rival's 9.99 dollar price point.
- The rival provides offline access, ensuring functionality in clinical environments without reliable network connectivity.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for BiliAAP
Where is it heading?
Bottom line
BiliAAP serves as a specialized clinical calculator for managing neonatal jaundice, marketed as a tool for bedside decision-making.
Report last updated